147 related articles for article (PubMed ID: 17696782)
1. Josephin domain-containing proteins from a variety of species are active de-ubiquitination enzymes.
Tzvetkov N; Breuer P
Biol Chem; 2007 Sep; 388(9):973-8. PubMed ID: 17696782
[TBL] [Abstract][Full Text] [Related]
2. Flanking domain stability modulates the aggregation kinetics of a polyglutamine disease protein.
Saunders HM; Gilis D; Rooman M; Dehouck Y; Robertson AL; Bottomley SP
Protein Sci; 2011 Oct; 20(10):1675-81. PubMed ID: 21780213
[TBL] [Abstract][Full Text] [Related]
3. Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3.
Haacke A; Broadley SA; Boteva R; Tzvetkov N; Hartl FU; Breuer P
Hum Mol Genet; 2006 Feb; 15(4):555-68. PubMed ID: 16407371
[TBL] [Abstract][Full Text] [Related]
4. Understanding the role of the Josephin domain in the PolyUb binding and cleavage properties of ataxin-3.
Nicastro G; Todi SV; Karaca E; Bonvin AM; Paulson HL; Pastore A
PLoS One; 2010 Aug; 5(8):e12430. PubMed ID: 20865150
[TBL] [Abstract][Full Text] [Related]
5. Interactions of ataxin-3 with its molecular partners in the protein machinery that sorts protein aggregates to the aggresome.
Bonanomi M; Mazzucchelli S; D'Urzo A; Nardini M; Konarev PV; Invernizzi G; Svergun DI; Vanoni M; Regonesi ME; Tortora P
Int J Biochem Cell Biol; 2014 Jun; 51():58-64. PubMed ID: 24685680
[TBL] [Abstract][Full Text] [Related]
6. Mode of substrate recognition by the Josephin domain of ataxin-3, which has an endo-type deubiquitinase activity.
Satoh T; Sumiyoshi A; Yagi-Utsumi M; Sakata E; Sasakawa H; Kurimoto E; Yamaguchi Y; Li W; Joazeiro CA; Hirokawa T; Kato K
FEBS Lett; 2014 Nov; 588(23):4422-30. PubMed ID: 25448680
[TBL] [Abstract][Full Text] [Related]
7. Functional interactions as a survival strategy against abnormal aggregation.
Masino L; Nicastro G; Calder L; Vendruscolo M; Pastore A
FASEB J; 2011 Jan; 25(1):45-54. PubMed ID: 20810784
[TBL] [Abstract][Full Text] [Related]
8. In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis.
Williams AJ; Knutson TM; Colomer Gould VF; Paulson HL
Neurobiol Dis; 2009 Mar; 33(3):342-53. PubMed ID: 19084066
[TBL] [Abstract][Full Text] [Related]
9. Ataxin-3 binds VCP/p97 and regulates retrotranslocation of ERAD substrates.
Zhong X; Pittman RN
Hum Mol Genet; 2006 Aug; 15(16):2409-20. PubMed ID: 16822850
[TBL] [Abstract][Full Text] [Related]
10. The Josephin domain (JD) containing proteins are predicted to bind to the same interactors: Implications for spinocerebellar ataxia type 3 (SCA3) studies using
Sousa E Silva R; Sousa AD; Vieira J; Vieira CP
Front Mol Neurosci; 2023; 16():1140719. PubMed ID: 37008788
[TBL] [Abstract][Full Text] [Related]
11. Proteotoxic stress increases nuclear localization of ataxin-3.
Reina CP; Zhong X; Pittman RN
Hum Mol Genet; 2010 Jan; 19(2):235-49. PubMed ID: 19843543
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the structure and the amyloidogenic properties of the Josephin domain of the polyglutamine-containing protein ataxin-3.
Masino L; Nicastro G; Menon RP; Dal Piaz F; Calder L; Pastore A
J Mol Biol; 2004 Dec; 344(4):1021-35. PubMed ID: 15544810
[TBL] [Abstract][Full Text] [Related]
13. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
[TBL] [Abstract][Full Text] [Related]
14. Structural and functional analysis of ataxin-2 and ataxin-3.
Albrecht M; Golatta M; Wüllner U; Lengauer T
Eur J Biochem; 2004 Aug; 271(15):3155-70. PubMed ID: 15265035
[TBL] [Abstract][Full Text] [Related]
15. The polyglutamine neurodegenerative protein ataxin 3 regulates aggresome formation.
Burnett BG; Pittman RN
Proc Natl Acad Sci U S A; 2005 Mar; 102(12):4330-5. PubMed ID: 15767577
[TBL] [Abstract][Full Text] [Related]
16. Ataxin-3 represses transcription via chromatin binding, interaction with histone deacetylase 3, and histone deacetylation.
Evert BO; Araujo J; Vieira-Saecker AM; de Vos RA; Harendza S; Klockgether T; Wüllner U
J Neurosci; 2006 Nov; 26(44):11474-86. PubMed ID: 17079677
[TBL] [Abstract][Full Text] [Related]
17. SUMO-1 modification on K166 of polyQ-expanded ataxin-3 strengthens its stability and increases its cytotoxicity.
Zhou YF; Liao SS; Luo YY; Tang JG; Wang JL; Lei LF; Chi JW; Du J; Jiang H; Xia K; Tang BS; Shen L
PLoS One; 2013; 8(1):e54214. PubMed ID: 23382880
[TBL] [Abstract][Full Text] [Related]
18. Investigation of the Josephin Domain protein-protein interaction by molecular dynamics.
Deriu MA; Grasso G; Licandro G; Danani A; Gallo D; Tuszynski JA; Morbiducci U
PLoS One; 2014; 9(9):e108677. PubMed ID: 25268243
[TBL] [Abstract][Full Text] [Related]
19. Elucidation of ataxin-3 and ataxin-7 function by integrative bioinformatics.
Scheel H; Tomiuk S; Hofmann K
Hum Mol Genet; 2003 Nov; 12(21):2845-52. PubMed ID: 12944423
[TBL] [Abstract][Full Text] [Related]
20. A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice.
Colomer Gould VF; Goti D; Pearce D; Gonzalez GA; Gao H; Bermudez de Leon M; Jenkins NA; Copeland NG; Ross CA; Brown DR
Neurobiol Dis; 2007 Sep; 27(3):362-9. PubMed ID: 17632007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
